| Date | Title | Description |
| 25.06.2024 | Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO & CDMO services | SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to ... |
| 12.03.2024 | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | - |
| 12.03.2024 | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | ROCKVILLE, Md., March 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization o... |
| 04.03.2024 | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results | ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of... |
| 09.08.2023 | MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance | ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well ... |
| 28.09.2022 | MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program | Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies
ROCKVILLE, Md., Sept. 28, 2022 (GLOBE ... |
| 07.09.2022 | MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference | ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well... |
| 10.08.2022 | MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results | 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022
Raises 2022 Core Revenue Growth Guidance to Approximately 30%
ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading comme... |
| 15.07.2022 | MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022 | GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as we... |
| 12.07.2022 | MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs | GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as we... |
| 13.05.2022 | MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as wel... |
| 09.05.2022 | MaxCyte Reports First Quarter Financial Results | GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as wel... |
| 03.05.2022 | MaxCyte to Participate in Upcoming Investor Conferences | GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as wel... |
| 15.04.2022 | MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based researc... |
| 12.04.2022 | MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue | GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as w... |
| 22.03.2022 | MaxCyte Reports Fourth Quarter and Full Year Financial Results | GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as... |
| 09.03.2022 | MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer | GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based researc... |
| 24.02.2022 | MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022 | GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based researc... |
| 12.02.2022 | MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 11.02.2022 | MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 01.02.2022 | MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs | NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic ... |
| 24.01.2022 | MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results | Fourth quarter 2021 revenue expected to be greater than $10 million
Full year 2021 revenue expected to be greater than $33.7 million
Installed base of greater than 500 instruments
15 SPLs, covering more than 95 programs, of which over 15% h... |
| 12.11.2021 | MaxCyte to Participate in Upcoming Investor Conferences | GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 11.11.2021 | MaxCyte Reports Third Quarter Financial Results | GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 10.11.2021 | MaxCyte Reports Third Quarter Financial Results | GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 03.11.2021 | MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board | GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based resear... |
| 29.10.2021 | Result of AGM | GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 28.10.2021 | MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs | SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a... |
| 28.10.2021 | MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs | Nkarta to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates
SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ... |
| 25.10.2021 | MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021 | GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research... |
| 20.04.2021 | MaxCyte : 2020 Full Year Results | MaxCyte, Inc.
('MaxCyte' or the 'Company')
MaxCyte Reports Final Results for the Year Ended 31 December 2020
Gaithersburg, Maryland -20 April 2021:MaxCyte (LSE: MXCT, MXCL, MXCN),a leading provider of cell-engineering platform technologies ... |
| 09.11.2020 | CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting | |
| 18.08.2020 | CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11 | |
| 17.09.2018 | Here’s a look at Maryland’s publicly-traded biotech companies | When talk turns to Maryland’s biotech bonafides, the ideas and talent being produced by government institutions like NIH, and research-oriented universities with connected health systems such as Johns Hopkins and University of Maryland are ... |
| 26.05.2017 | Here’s who won TEDCO’s 2017 ICE awards | TEDCO’s ICE awards returned to Columbus Center in Inner Harbor on Thursday night.
The Maryland agency, which provides resources for startups and other businesses, awards portfolio companies for Innovation, Corporate Excellence and Entrepren... |
| 13.01.2017 | HGP – MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies | – Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform
– CARMA has potential for broad applicability against solid or liquid tumor indications |
| 13.01.2017 | HGP – MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene | Gaithersburg, MD, January 12, 2017 – MaxCyte®, Inc., a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery
and development, biomanufacturing, gene editing a... |
| 15.09.2015 | HVP – MaxCyte Appoints Chayon Laboratories as Distributor in Korea for the MaxCyte STX® and MaxCyte VLX® | Gaithersburg, MD, September 15, 2015 – MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, announces the appointment of Chayon Laboratories as the exclusive authorized distributor of the MaxCyte STX® Scalabl... |
